IE950955A1 - Compounds. - Google Patents

Abstract

Antibiotic and mucolytic salts of roxithromycin clarithromycin and azithromycin are described. Particularly described is roxithromycin stinoprate which was found to be more potent that erythromycin stinoprate.

Description

Antibiotic and mucolytic salts of roxithromycin clarithromycin and azithromycin are described. Particularly described is roxithromycin stinoprate which was found to be more potent that erythromycin stinoprate.

Introduction The present invention relates to new antibiotic and mucolytic salts of roxithromycin, clarithromycin and azithromcyin.

The exploitation of the therapeutical properties of thiolic compounds in combination with the properties of antibiotics has been attempted as described in EP 0,057,489A. However, it has been found that acetylcysteine and the derivatives thereof are relatively unstable and especially sensitive to oxygen, sunlight, humidity and heat.

The invention is directed towards providing antibiotic and mucolytic salts .

Statements of Invention The derivatives according to the present invention have the following general formula : O n NH-C-CH3 I HS-CH^CH-COO x RH wherein R is a radical selected from : Roxithromycin, Clarithromycin and Azithromycin.

It has been surprisingly found that the compounds of the 20 present invention are very stable, and can be therapeutically used on KT eLBbLK <_O + C 3 2.3 13- /O* have very low toxicity cB-aany.---OPEN TO PUBLIC INSPECTION UN It R SECTION 28 AND RULE 23 JNL. No../..?.5.3.......OF β/'? G - 2 These new derivatives of the below mentioned macrolides have the further advantages of :(a) better oral absorption; (b) faster and superior concentration; (c) slow elimination; and/or (d) reduced dosage : only 300 - 500 mg per day.

Roxithromycin has the structure Clarithromycin has the structure CHfA—OH - 3 Azithromycin has the structure The compounds according to the invention are white microcrystalline powders.

Their use is foreseen in all pharmaceutical forms and the 5 compounds may be provided in any suitable pharmaceutical composition including : capsules; solutions; injectable preparations; aerosols; effervescent tablets; powders; creams; and suspensions. The pharmaceutical compositions will typically contain suitable excipients and/or vehicles which are conventionally used in galenical pharmacy.

The method for the preparation of the new salts comprises reacting roxithromycin, clarithromycin or azithromycin base with N-acetylcystein in a stoichiometrical ratio or preferably with a slight excess of the antibiotic nucleus.

Most preferably the reaction is carried out in an organic solvent, at a temperature of between 20 and 40°C and in the presence of water, preferably in an amount of not greater than 20%. Alternatively, the reactions may be carried out in a suspension of water at a temperature of 20 and 40°C, (with N-acetylcystein in a stoichiometrical ratio or in - 4 the presence of a slight excess of the antibiotic nucleus), and after building the salts, water is distilled off under very mild conditions (low vacuum, low temperature).

Example Salt of roxithromycin with N-acetylcystein 1800 g of Roxithromycin and 350.9 g of N-acetylcystein are homogenised under inert conditions (nitrogen) for 60 minutes at 15-20°C. To this mixture 720 ml of deionised water is added at atmospheric pressure and further homogenised for one hour at 15-20°C. The product is dried under vacuum and milled, if necessary. A yield of 79.8% (1716 g) is obtained.

The Infra Red spectrum of the compound is plotted in Fig. 1.

The salts of clarithromycin and azithromycin are produced in a similar manner to that described in the above example.

MICROBIOLOGICAL ASSAY OF ROXITHROMYCIN STINOPRATE References: USP 23 <81> Antibiotics-Microbial Assays, page 1690-1696 Code of Federal Regulations Title 21 :436.100 - 436.106 Test Organism: Staphylococcus aureus ATCC 29737 The test organism was maintained through periodic inoculations on agar slants containing USP 23 Medium No. 1. The slants are incubated at 32-35°C for 24 hours, and Ο Ο *ϊ * - 5 stored under refrigeration.

Assay Receptacles: Sterile plastic petri-dishes (ca. 20 x 100mm) with covers were used as assay plates . Assay cylinders were manufactured from stainless steel (o.d. 8mm + 0.1mm, i.d. 6mm + 0.1mm, length 10mm + 0.1mm).

Inoculum Preparation: Using 5ml of sterile USP Saline T.S. the 10 growth from an agar slant of S. aureus was washed and made up to 50ml with sterile saline solution. This stock suspension was diluted with sterile saline so that the transmittance, at 580nm, was 25% against saline as the blank. lml of this solution (i.e. giving 25% transmission) was added to each 100ml of culture media (USP 23 Medium No. 1 (Oxoid Antibiotic Medium No. 1)).

Culture Medium: Oxoid Antibiotic Medium No. 1.

Solutions: Saline Solution (sterile) Sodium chloride 0.9g Purified Water 100ml Sterilised at 121°C for 20 minutes.

Buffer Solution No. 3 (USP 23) (0.1M potassium phosphate buffer pH 8.0) Dibasic potassium phosphate 16.73g Monobasic potassium phosphate 0.523g * 950955 - 6 Purified Water 1000ml Adjusted with ION potassium hydroxide to give a pH 7.9-8.1. Sterilised at 121°C for 20 minutes .

Standards: Erythromycin Stinoprate Standards: About lOOmg of Erythromycin Stinoprate standard, accurately weighed, was added to a 100ml volumetric flask. 10ml of methanol was added to dissolve the Erythromycin Stinoprate. contains 1Omg/ml of Stinoprate. A 1:10 dilution of this solution was then prepared with sterile buffer solution to obtain a 1000 pg/ml Erythromycin Stinoprate solution.

This solution Erythromycin From this stock solution the following dilutions were prepared: 1.56 pg/ral (S5); 1.25 pg/ml (S4); 1.0 pg/ml (S3); 0.8 pg/ml (S2) 7 and 0.64 pg/ml (SJ (using sterile buffer solution for dilutions) Test Sample (Roxithromycin Stinoprate): About lOOmg of Roxithromycin embonate test substance, accurately weighed, was added to a 100ml volumetric flask. 10ml of methanol was added for dissolution and this in turn was diluted with sterile buffer solution to obtain a 1000 pg/ml Roxithromycin Stinoprate solution. - 7 From this stock solution a solution was prepared containing 1.0 gg/ml Roxithromycin Stinoprate, using sterile buffer solution for dilution purposes (U3).

Method: Cylinder-Plate Method USP 23 <81> Approximately 20ml of sterilised Oxoid Antibiotic Medium No. 1 was placed in each of 22 sterile petri-dishes, and allowed to harden. Using the inoculum described above 5.0ml of seed layer inoculum were added to each plate except two plates which were reserved as negative controls. Six (6) stainlesssteel assay cylinders were dropped on the inoculated surfaces of 18 of the plates from a height of 12mm, with even spacing on a radius of 28mm. The remaining two inoculated plates were retained as positive controls.

Using a 1-level assay with standard curve, alternate cylinders on each of three plates were filled with the 1.0 pg/ml solution of Erythromycin Stinoprate (S3), and each of the remaining nine cylinders were filled with one of the four other dilutions of the Standard (Si - S5) . This process was repeated for the other three dilutions of the standard.

The 1.0 gg/ml solution of Erythromycin Stinoprate (S3) was filled into alternate cylinders on each of three plates and ^950955 - 8 the remaining nine cylinders were filled with the Test Sample (U3) .

Incubation: 24 hours at 32-35°C Estimation of Potency: The potency of the Roxithromycin Stinoprate test substance was compared to the standard curve obtained for the Erythromycin Stinoprate standard dilutions. This was calculated as a percentage of the potency of the 1.0 gg/ml Erythromycin Stinoprate standard dilution.

Results: Roxithromycin Stinoprate Mean potency (x) = 114% (of Erythromycin Stinoprate).

Standard deviation (s.d.) = 2.94%. Coefficient of variation (c.v.) = 2.56%.

The invention is not limited to the embodiments hereinbefore described which may be varied in detail.

Claims (12)

1. CTJKIMS

1. A compound of the formula

O II NH-C-CH3 HS-CHj-CH-COO * X RH* 5 2. wherein R is a radical selected from : Roxithromycin, Clarithromycin and Azithromycin. N-Acetylcystein-Roxithromycin Salt.

3. N-AcetyIcystein-Clarithromycin Salt.

4 . N-Acetylcystein-Azithromycin Salt.

5. A compound substantially as hereinbefore described with reference to the examples. 10

6. A pharmaceutical composition comprising a compound as claimed in any preceding claim together with at least one pharmaceutically acceptable excipient and/or carrier.

7 . A process for preparing a compound of the formula O I NHOCH3 . HS-CHyCI+COO * RH 950959 - 10 wherein R is a radical selected from : Roxithromycin, Clarithromycin and Azithromycin. comprising the step of reacting N-Acetylcystein with roxithromycin, clarithromycin or azithromycin 5 base.

8.

9. A process as claimed in claim 7 wherein the reaction is carried out in an organic solvent. A process as claimed in claim 7 or 8 wherein the reaction is carried out in an aqueous medium.

10 10. A process as claimed in any of claims 7 to 9 wherein the reaction is carried out at a temperature of from 20°C to 40°C.

11. A process substantially as hereinbefore described with reference to the Examples. 15

12. A compound whenever prepared by a process as claimed in any of claims 7 to 11.